GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp
- First Posted Date
- 2008-04-30
- Last Posted Date
- 2017-06-06
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 89
- Registration Number
- NCT00669214
An Observational Study of TNKase in Patients Enrolled in the National Registry of Myocardial Infarction 4 and 5 (POST)
Completed
- Conditions
- First Posted Date
- 2008-04-29
- Last Posted Date
- 2017-02-15
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 253668
- Registration Number
- NCT00669045
A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2008-04-23
- Last Posted Date
- 2022-12-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT00664898
Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 1058
- Registration Number
- NCT00662038
- Locations
- 🇺🇸
Genentech, Inc., South San Francisco, California, United States
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2017-06-08
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 199
- Registration Number
- NCT00636610
A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)
- First Posted Date
- 2008-02-29
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 381
- Registration Number
- NCT00626197
GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2015-10-08
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 68
- Registration Number
- NCT00607724
A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-12-04
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 808
- Registration Number
- NCT00567190
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸LAC USC Medical Center, Los Angeles, California, United States
🇺🇸St. Barnabas Cancer Center, Livingston, New Jersey, United States
A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma
- First Posted Date
- 2007-11-12
- Last Posted Date
- 2014-03-20
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT00556699
A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-10-24
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 774
- Registration Number
- NCT00548548
- Locations
- 🇺🇸
Cancer Center of Kansas, Wichita, Kansas, United States
🇺🇸Georgetown University, Washington, D.C., District of Columbia, United States
🇺🇸USC/Norris Cancer Center, Los Angeles, California, United States
© Copyright 2024. All Rights Reserved by MedPath